Related Experiment Video
Updated: Sep 2, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Childhood tuberculosis
Lindsay H Cameron1, Andrea T Cruz1,2
1Department of Pediatrics, Sections of Infectious Diseases.
Insights
Identifying children at risk for tuberculosis requires updated strategies. Recent advancements in interferon gamma release assays (IGRAs) and molecular testing aid diagnosis, while shorter treatment regimens are available but have limitations.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- The management of pediatric tuberculosis (TB) is increasingly complex due to the SARS-CoV-2 pandemic, broader use of immunosuppressants, and evolving treatment protocols.
- New diagnostic tools and shorter treatment regimens have emerged, but their application requires careful consideration of patient factors and potential drug interactions.
Purpose of the Study:
- To review the latest literature on identifying children at risk for tuberculosis.
- To outline optimal testing and treatment strategies for pediatric tuberculosis.
- To address the challenges posed by the SARS-CoV-2 pandemic and other factors on TB management in children.
Main Methods:
- Literature review of recent studies on pediatric tuberculosis diagnosis and treatment.
- Analysis of the impact of SARS-CoV-2 pandemic on global TB control efforts.
- Evaluation of interferon gamma release assays (IGRAs) and molecular-based tests for TB diagnosis in children.
Main Results:
- The SARS-CoV-2 pandemic is expected to negatively affect global tuberculosis control.
- Interferon gamma release assays (IGRAs) and molecular-based testing show promise for improving pediatric TB diagnosis.
- Shorter, rifamycin-containing treatment regimens are available for pediatric TB infection, but drug-drug interactions limit their use in some immunosuppressed children.
Conclusions:
- A comprehensive approach to identifying and managing children at risk for tuberculosis is crucial.
- Enhanced utilization of IGRAs and molecular-based testing is supported by growing evidence for improved pediatric TB diagnosis.
- Providers must remain aware of the challenges impacting pediatric TB identification and treatment, including pandemic-related disruptions and limitations of shorter treatment regimens in specific populations.
Purpose Of Review:
We discuss the most recent literature to support the identification of children at risk for tuberculosis and optimal testing and treatment strategies.
Recent Findings:
The identification and management of children with tuberculosis has increased in complexity due to the recent severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic, greater use of immunosuppressive agents, and the administration of shorter, rifamycin-containing treatment regimens. Advancements in the diagnosis and treatment of tuberculosis in children include: use of interferon gamma release assays (IGRAs); molecular-based tests; and shorter courses of treatment. While the essential steps to identify and treat children at risk for tuberculosis remain unchanged, providers must be aware of impact of these challenges.
Summary:
The SARS-CoV-2 pandemic will likely have a negative impact on global tuberculosis control. It is important that countries maintain a comprehensive approach to the identification and management of children at risk for tuberculosis. Increasing evidence supports enhanced utilization of IGRAs and molecular-based testing to improve the diagnosis of tuberculosis in children. Shorter course, rifamycin-based treatment regimens are available to treat children with tuberculosis infection; however, their use is limited in some immunosuppressed children due to drug-drug interactions.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
09:34An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Other Pulmonary Disorders